•
Apr 03, 2021

Perrigo Q1 2021 Earnings Report

Perrigo's transformation into a consumer self-care company neared completion, with Q1 results reflecting pandemic-related distortions but remaining in line with expectations.

Key Takeaways

Perrigo reported a decrease in net sales and adjusted EPS for Q1 2021, primarily due to pantry loading in the prior year and a weak cough/cold season. However, the company reaffirmed its full-year guidance, citing strong business fundamentals and anticipated improvements in retail traffic and cough/cold incidence.

Net sales decreased by 6.8% to $1.01 billion, impacted by pantry loading and weak cough/cold season.

Adjusted diluted EPS decreased by 25.4% to $0.50, also affected by pandemic-related factors.

CSCA net sales decreased by 8.6% to $641 million, while CSCI net sales decreased by 3.4% to $370 million.

Fiscal year 2021 outlook reaffirmed, with expectations of 3% organic net sales growth, 5% adjusted operating income growth, and 7% adjusted diluted EPS growth.

Total Revenue
$1.01B
Previous year: $1.34B
-24.7%
EPS
$0.5
Previous year: $1.14
-56.1%
Adjusted Operating Income
$119M
Previous year: $151M
-21.6%
Gross Profit
$368M
Previous year: $483M
-23.8%
Cash and Equivalents
$471M
Previous year: $510M
-7.7%
Free Cash Flow
-$45.2M
Previous year: $138M
-132.8%
Total Assets
$11.3B
Previous year: $11.4B
-0.7%

Perrigo

Perrigo

Perrigo Revenue by Segment

Forward Guidance

The Company reaffirmed its fiscal 2021 outlook and expects to deliver 3% organic net sales growth, 5% adjusted operating income growth and 7% adjusted diluted EPS growth, translating into an adjusted diluted EPS range of $2.50 to $2.70.

Revenue & Expenses

Visualization of income flow from segment revenue to net income